Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study.
Klein-Scory S, Baraniskin A, Schmiegel W, Mika T, Schroers R, Held S, Heinrich K, Tougeron D, Modest DP, Schwaner I, Eucker J, Pihusch R, Stauch M, Kaiser F, Kahl C, Karthaus M, Müller C, Burkart C, Stintzing S, Heinemann V. Klein-Scory S, et al. Among authors: modest dp. Mol Oncol. 2024 Dec 4. doi: 10.1002/1878-0261.13778. Online ahead of print. Mol Oncol. 2024. PMID: 39630848 Free article.
Correction: Is interval chemotherapy safe and does it improve the outcome of patients with colorectal liver metastases undergoing multimodal two-stage hepatectomy? - A systematic literature review.
Raschzok N, Moosburner S, Blank M, Krenzien F, Lurje G, Schöning W, Sauer IM, Pratschke J, Modest DP, Kurreck A. Raschzok N, et al. Among authors: modest dp. BMC Cancer. 2024 Nov 11;24(1):1382. doi: 10.1186/s12885-024-13152-2. BMC Cancer. 2024. PMID: 39528976 Free PMC article. No abstract available.
Is interval chemotherapy safe and does it improve the outcome of patients with colorectal liver metastases undergoing multimodal two-stage hepatectomy? - A systematic literature review.
Raschzok N, Moosburner S, Blank M, Krenzien F, Lurje G, Schöning W, Sauer IM, Pratschke J, Modest DP, Kurreck A. Raschzok N, et al. Among authors: modest dp. BMC Cancer. 2024 Oct 10;24(1):1260. doi: 10.1186/s12885-024-13008-9. BMC Cancer. 2024. PMID: 39390396 Free PMC article.
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma.
Lozzi I, Arnold A, Barone M, Johnson JC, Sinn BV, Eschrich J, Gebert P, Wang R, Hu M, Feldbrügge L, Schirmeier A, Reutzel-Selke A, Malinka T, Krenzien F, Schöning W, Modest DP, Pratschke J, Sauer IM, Felsenstein M. Lozzi I, et al. Among authors: modest dp. Oncoimmunology. 2024 Oct 1;13(1):2406052. doi: 10.1080/2162402X.2024.2406052. eCollection 2024. Oncoimmunology. 2024. PMID: 39359389 Free PMC article.
Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series.
Platt JR, Allotey J, Alouani E, Glasbey J, Intini R, Lonardi S, Mazzoli G, Militello AM, Modest DP, Palle J, Pietrantonio F, Riyad K, Samuel L, Schulze AV, Shiu KK, Taieb J, Tolan DJM, West NP, Westwood AC, Williams CJM, Seligmann JF. Platt JR, et al. Among authors: modest dp. ESMO Open. 2024 Sep;9(9):103698. doi: 10.1016/j.esmoop.2024.103698. Epub 2024 Sep 5. ESMO Open. 2024. PMID: 39241497 Free PMC article.
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.
Alig AHS, Modest DP, Stintzing S, Heinrich K, Geissler M, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Held S, Moosmann N, Stahler A, Tannapfel A, Giessen-Jung C, Jung A, Weiss L, Heinemann V. Alig AHS, et al. Among authors: modest dp. ESMO Open. 2024 Sep;9(9):103677. doi: 10.1016/j.esmoop.2024.103677. Epub 2024 Aug 21. ESMO Open. 2024. PMID: 39173562 Free PMC article.
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.
Dorman K, Boeck S, Caca K, Reichert M, Ettrich TJ, Oettle H, Waidmann O, Modest DP, Müller L, Michl P, Kanzler S, Pink D, Reinacher-Schick A, Geißler M, Pelz H, Kunzmann V, Held S, Schichtl T, Heinemann V, Kullmann F. Dorman K, et al. Among authors: modest dp. Lancet Gastroenterol Hepatol. 2024 Oct;9(10):935-943. doi: 10.1016/S2468-1253(24)00197-3. Epub 2024 Aug 16. Lancet Gastroenterol Hepatol. 2024. PMID: 39159648 Clinical Trial.
Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial.
Ballhausen A, Karthaus M, Fruehauf S, Graeven U, Müller L, König AO, von Weikersthal LF, Sommerhäuser G, Jelas I, Alig AHS, Kurreck A, Stahler A, Goekkurt E, Held S, Kasper S, Heinrich K, Heinemann V, Stintzing S, Trarbach T, Modest DP. Ballhausen A, et al. Among authors: modest dp. ESMO Open. 2024 Jul;9(7):103628. doi: 10.1016/j.esmoop.2024.103628. Epub 2024 Jul 13. ESMO Open. 2024. PMID: 38996519 Free PMC article. Clinical Trial.
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer.
Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Élez E, Wyrwicz L, Stroyakovskiy D, Liposits G, Bondarenko I, Modest DP, Amellal N, Tabernero J; SUNLIGHT Investigators. Prager GW, et al. Among authors: modest dp. Future Oncol. 2024;20(36):2823-2832. doi: 10.1080/14796694.2024.2366100. Epub 2024 Jul 2. Future Oncol. 2024. PMID: 38953855 Free PMC article. Clinical Trial.
142 results